Literature DB >> 14627343

Coexpression of IGF-1R and c-Src proteins in human pancreatic ductal adenocarcinoma.

Ardeshir Hakam1, Quan Fang, Richard Karl, Domenico Coppola.   

Abstract

Aberrant c-Src protein kinase activation has been identified as one of the molecular alterations involved in human pancreatic carcinogenesis. It has been postulated that c-Src may induce transformation by causing the overexpression of the insulinlike growth factor-1 receptor (IGF-1R) in pancreatic tumor cell lines. To further study the interaction between c-Src and IGF-1R proteins in human pancreatic cancer, we examined their coexpression in 47 human pancreatic ductal adenocarcinomas (PDA). Formalin-fixed, paraffin-embedded sections from 47 cases of PDA were stained using the immunohistochemical avidin-biotin-peroxidase method. We used an anti-human IGF-1R mouse monoclonal antibody (dilution 1:100 with antigen retrieval), and an anti-c-Src mouse monoclonal antibody (dilution 1:100 with antigen retrieval). The stains were semiquantitatively evaluated using the Allred score system, assessing intensity of stain and percentage of positive tumor cells. High cytoplasmic c-Src expression (Allred score 7-8) was seen in 33/47 (70%) tumors. In only 4 cases was c-Src either negative or low (Allred score 3). Strong and diffuse membranous IGF-1R stain (Allred score 7-8) was identified in 30/47 (64%) tumors. IGF-1R staining was low (Alled score 2-4) in 2 cases and negative in 1. Interestingly, in 40/47 (85%) cases c-Src and IGF-1R stains had similar scores. An inverse staining pattern was detected in only 6/47 (13%) tumors. Normal pancreatic ducts as well as areas of chronic pancreatitis were negative for IGF-1R. In conclusion, our data support the role of IGF-1R and c-Src in human pancreatic carcinogenesis; the coexpression of both these molecules may play an important role in transformation of pancreatic ductal cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14627343     DOI: 10.1023/a:1026122421369

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  50 in total

Review 1.  Survival statistics gone awry: pancreatic cancer, a case in point.

Authors:  Birgir Gudjonsson
Journal:  J Clin Gastroenterol       Date:  2002-08       Impact factor: 3.062

2.  A tail of two src's: mutatis mutandis.

Authors:  T Hunter
Journal:  Cell       Date:  1987-04-10       Impact factor: 41.582

3.  Transforming growth factor beta and cell cycle regulation.

Authors:  M G Alexandrow; H L Moses
Journal:  Cancer Res       Date:  1995-04-01       Impact factor: 12.701

4.  Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells.

Authors:  R Garcia; T L Bowman; G Niu; H Yu; S Minton; C A Muro-Cacho; C E Cox; R Falcone; R Fairclough; S Parsons; A Laudano; A Gazit; A Levitzki; A Kraker; R Jove
Journal:  Oncogene       Date:  2001-05-03       Impact factor: 9.867

5.  Differential expression of CD44v6 in adenocarcinoma of the pancreas: an immunohistochemical study.

Authors:  E M Castellà; A Ariza; I Ojanguren; J L Mate; X Roca; A Fernández-Vasalo; J J Navas-Palacios
Journal:  Virchows Arch       Date:  1996-11       Impact factor: 4.064

6.  Transforming growth factor alpha and epidermal growth factor in human pancreatic cancer.

Authors:  C M Barton; P A Hall; C M Hughes; W J Gullick; N R Lemoine
Journal:  J Pathol       Date:  1991-02       Impact factor: 7.996

7.  Activating SRC mutation in a subset of advanced human colon cancers.

Authors:  R B Irby; W Mao; D Coppola; J Kang; J M Loubeau; W Trudeau; R Karl; D J Fujita; R Jove; T J Yeatman
Journal:  Nat Genet       Date:  1999-02       Impact factor: 38.330

8.  Prognostic value of immunohistochemical expression of p53 in patients with pancreatic cancer.

Authors:  J Lundin; S Nordling; K von Boguslawsky; P J Roberts; C Haglund
Journal:  Oncology       Date:  1996 Mar-Apr       Impact factor: 2.935

9.  c phosphorylation and activation of the IGF-I receptor in src-transformed cells.

Authors:  J E Peterson; T Jelinek; M Kaleko; K Siddle; M J Weber
Journal:  J Biol Chem       Date:  1994-11-04       Impact factor: 5.157

10.  Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma.

Authors:  D Cantero; H Friess; J Deflorin; A Zimmermann; M A Bründler; E Riesle; M Korc; M W Büchler
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more
  30 in total

Review 1.  Chemoprevention strategies for pancreatic cancer.

Authors:  Silvia D Stan; Shivendra V Singh; Randall E Brand
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-05-04       Impact factor: 46.802

Review 2.  Pancreatic cancer: molecular pathogenesis and new therapeutic targets.

Authors:  Han H Wong; Nicholas R Lemoine
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-06-09       Impact factor: 46.802

Review 3.  Metformin in pancreatic cancer treatment: from clinical trials through basic research to biomarker quantification.

Authors:  Archana Bhaw-Luximon; Dhanjay Jhurry
Journal:  J Cancer Res Clin Oncol       Date:  2016-05-09       Impact factor: 4.553

4.  The prognostic role of phospho-Src family kinase analysis in tongue cancer.

Authors:  Ofer Ben-Izhak; Victoria Cohen-Kaplan; Rafael M Nagler
Journal:  J Cancer Res Clin Oncol       Date:  2010-01       Impact factor: 4.553

5.  A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors.

Authors:  Niharika B Mettu; Donna Niedzwiecki; Christel Rushing; Andrew B Nixon; Jingquan Jia; Sherri Haley; Wanda Honeycutt; Herbert Hurwitz; Johanna C Bendell; Hope Uronis
Journal:  Cancer Chemother Pharmacol       Date:  2019-03-20       Impact factor: 3.333

6.  IGF-1R peptide vaccines/mimics inhibit the growth of BxPC3 and JIMT-1 cancer cells and exhibit synergistic antitumor effects with HER-1 and HER-2 peptides.

Authors:  Kevin Chu Foy; Megan J Miller; Jay Overholser; Siobhan M Donnelly; Rita Nahta; Pravin Tp Kaumaya
Journal:  Oncoimmunology       Date:  2014-12-21       Impact factor: 8.110

7.  KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling.

Authors:  Victoria A Appleman; Leanne G Ahronian; JiuFeng Cai; David S Klimstra; Brian C Lewis
Journal:  Mol Cancer Res       Date:  2012-08-07       Impact factor: 5.852

8.  Insulin-Like Growth Factor-1 Receptor Expression and Disease Recurrence and Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma.

Authors:  Chunxia Du; Annacarolina da Silva; Vicente Morales-Oyarvide; Brian M Wolpin; Jonathan A Nowak; Andressa Dias Costa; Margaret M Kozak; Richard F Dunne; Douglas A Rubinson; Kimberly Perez; Yohei Masugi; Tsuyoshi Hamada; Lauren K Brais; Chen Yuan; Ana Babic; Matthew D Ducar; Aaron R Thorner; Andrew Aguirre; Matthew H Kulke; Kimmie Ng; Thomas E Clancy; Jennifer J Findeis-Hosey; Daniel T Chang; Jason L Hornick; Charles S Fuchs; Shuji Ogino; Albert C Koong; Aram F Hezel
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-05-28       Impact factor: 4.254

9.  Depleting MEKK1 expression inhibits the ability of invasion and migration of human pancreatic cancer cells.

Authors:  Fuqin Su; Hongyan Li; Chaoqi Yan; Baoqing Jia; Yi Zhang; Xiaoguang Chen
Journal:  J Cancer Res Clin Oncol       Date:  2009-06-10       Impact factor: 4.553

Review 10.  Current update on established and novel biomarkers in salivary gland carcinoma pathology and the molecular pathways involved.

Authors:  Markus Stenner; J Peter Klussmann
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-12-04       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.